# A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects

> **NCT01291602** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 15 (actual)

## Conditions studied

- Healthy Male and Female Japanese Volunteers

## Interventions

- **DRUG:** NXL104
- **DRUG:** CAZ104
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01291602
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01291602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01291602, "A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01291602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*